A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension

Trial Profile

A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jul 2018

At a glance

  • Drugs Bardoxolone methyl (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms LARIAT
  • Sponsors Reata Pharmaceuticals
  • Most Recent Events

    • 08 Jun 2018 Status changed from active, no longer recruiting to completed.
    • 31 May 2018 This trial has been completed in Spain (end date: 2018-05-16)
    • 23 May 2018 Results assessing eGFR changes as prognostic factor in Connective Tissue Disease PAH patients (n=22) presented at the 114th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top